What's Happening?
The Centers for Medicare and Medicaid Services (CMS) has proposed changes to the payment structure for diabetes technology, including insulin pumps and continuous glucose monitors. The proposal suggests incorporating these devices into a competitive bidding program and shifting payments to a monthly rental schedule. Companies like Tandem Diabetes Care and Insulet are monitoring the situation, with Tandem expecting minimal impact due to its current sales model. Insulet, which already operates on a pay-as-you-go basis, anticipates little effect from the changes. The proposal aims to drive more people to pump therapy, potentially altering market dynamics.
AD
Why It's Important?
The CMS proposal could significantly impact the diabetes technology industry, affecting how companies price and distribute their products. By moving to a competitive bidding model, CMS aims to reduce costs, which could lead to increased competition among manufacturers. This shift may benefit consumers by potentially lowering prices and increasing access to advanced diabetes management tools. However, companies that rely on upfront payments may face challenges adapting to the new model, affecting their revenue and market strategies.
What's Next?
Stakeholders in the diabetes technology industry are expected to participate in the comment period, with final rulings anticipated in November. Companies may need to adjust their business models to align with the new payment structure, potentially leading to strategic shifts in product offerings and distribution channels. The competitive bidding process is projected to start no earlier than 2027, giving companies time to prepare for the changes.
